Key Performance Indicators of Clinical Trials in JapanImplications for Reducing the Drug Lag

被引：0
|
作者：
Michinori Terada
Mamoru Narukawa
Masahiro Takeuchi
机构：
[1] Kitasato University,Department of Pharmaceutical Medicines, Graduate School of Pharmaceutical Sciences
[2] Clinical Research,Tokyo Laboratories
[3] Pfizer Global R&D,undefined
来源：
Pharmaceutical Medicine | 2009年 / 23卷 / 5-6期
关键词：
Azithromycin; Recruitment Rate; Project Assistant; Source Data Verification; Investigational Review Board;
D O I：
10.1007/BF03256786
中图分类号：
学科分类号：
摘要：
Background: In Japan, the launch of new drugs is often delayed compared with other major regions, including the US and European countries. This so-called ‘drug lag’ is a significant problem because patients are being denied access to new and potentially life-saving therapies.
引用
收藏
页码：305 / 308
页数：3
相关论文
共 50 条
  • [21] Clinical Drug Trials
    Mason, Amy
    PEDIATRICS IN REVIEW, 2018, 39 (03) : 150 - 152
  • [22] Clinical pharmacy key performance indicators for hospital inpatient setting: a systematic review
    Magedanz, Lucas
    Silva, Hiolanda Ledo
    Galato, Dayani
    Fernandez-Llimos, Fernando
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, 46 (03) : 602 - 613
  • [23] Qualitative Thematic Analysis of Interprofessional Perspectives on Clinical Pharmacy Key Performance Indicators
    Fernandes, O.
    Raymond, C.
    Mourao, D.
    Meade, A.
    Toombs, K.
    Slobodan, J.
    Hao, B.
    Sreeskantharajan, S.
    Poggemoeller, K.
    Attfield, E.
    Gorman, S.
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2018, 71 (01): : 85 - 85
  • [24] Evaluating the Impact of Access and Flow Pharmacists on Clinical Pharmacy Key Performance Indicators
    Gellatly, R.
    Minhas, R.
    Kim, E.
    Sy, I
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2024, 77 (02):
  • [25] Pharmacists' Perceptions of the Barriers and Facilitators to the Implementation of Clinical Pharmacy Key Performance Indicators
    Minard, Laura V.
    Deal, Heidi
    Harrison, Megan E.
    Toombs, Kent
    Neville, Heather
    Meade, Andrea
    PLOS ONE, 2016, 11 (04):
  • [26] IMPLEMENTATION OF RENAL KEY PERFORMANCE INDICATORS IN VICTORIA: PROMOTING IMPROVED CLINICAL PRACTICE
    Toussaint, N. D.
    Dowling, G.
    Safe, M.
    Mcmahon, L. P.
    Knight, R.
    Fair, K.
    Linehan, L.
    Walker, R. G.
    Power, D. A.
    NEPHROLOGY, 2014, 19 : 72 - 73
  • [27] Effects of duration of follow-up and lag in data collection on the performance of adaptive clinical trials
    Granholm, Anders
    Lange, Theis
    Harhay, Michael O.
    Jensen, Aksel Karl Georg
    Perner, Anders
    Moller, Morten Hylander
    Kaas-Hansen, Benjamin Skov
    PHARMACEUTICAL STATISTICS, 2024, 23 (02) : 138 - 150
  • [28] KEY PERFORMANCE INDICATORS FOR AN SOP SYSTEM
    Schenk, M.
    VOX SANGUINIS, 2013, 105 : 86 - 86
  • [29] Human Resources Key Performance Indicators
    Gabcanova, Iveta
    JOURNAL OF COMPETITIVENESS, 2012, 4 (01) : 117 - 128
  • [30] Key Performance Indicators and the Balanced Scorecard
    Harvey, H. Benjamin
    Sotardi, Susan T.
    JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 2018, 15 (07) : 1000 - +
12345